

Amoxibactin 250 mg tablets for dogs

Authorised

- Amoxicillin trihydrate

Product identification

Medicine name:

Amoxibactin 250 mg tablets for dogs

Active substance:

Amoxicillin trihydrate

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate

287.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CA04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Available in:

Germany

Package description:

Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.

Cardboard box of 50 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. Beheer B.V.

Marketing authorisation date:

13/09/2022

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

Federal Office Of Consumer Protection And Food Safety

Authorisation number:

V7006863.00.00

Date of authorisation status change:

13/09/2022

Reference member state:

Netherlands

Procedure number:

NL/V/0186/002

Concerned member states:

Austria Belgium Cyprus Czechia Denmark Estonia Finland France Germany
Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway
Poland Portugal Romania Slovakia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 23/06/2026

Download